Ipsen SA, the French specialty pharma company, reported substantial increases in revenue and operating profit for 2016. It expects the momentum to continue in 2017 when its $1 billion acquisition of Onivyde (irinotecan liposome) for treating metastatic pancreatic cancer should be completed.
